MedPath

Intermetatarsal Bursitis in Patients with Rheumatoid Arthritis

Not Applicable
Active, not recruiting
Conditions
Intermetatarsal Bursitis
Rheumatoid Arthritis
Interventions
Diagnostic Test: Magnetic resonance imaging
Diagnostic Test: Ultrasound
Drug: Corticosteroid injection
Other: Clinical foot evaluation
Other: Picture of the feet
Registration Number
NCT05698563
Lead Sponsor
Rigshospitalet, Denmark
Brief Summary

The aim of the study is to investigate the incidence and clinical implications of intermetatarsal bursitis (IMB) in patients with rheumatoid arthritis (RA).

The hypothesis is that IMB is a cause of pain in patients with RA.

Detailed Description

Within the recent years more research have focused on IMB in patients with rheumatologic disorders. There is emerging evidence that IMB is an inflammatory alteration in line with synovitis in patients with RA, and presence of IMB have been linked to the early stages of RA, especially due to the focus of the published literature.

The clinical implications of the presence of IMB for the patients are yet to be understood. Limited studies have linked the occurrence of IMB to foot impairment, but no studies have been conducted investigating the direct association between forefoot pain and the presence/absence of IMB.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
105
Inclusion Criteria
  • Age > 18 years
  • Forefoot pain and diagnosed with RA (patient group)
  • Diagnosed with an axial arthritis (control group)
Exclusion Criteria
  • Age <18 years
  • Open wounds or ongoing infection in the forefoot at the time of examination
  • Persons with a history of significant trauma in the forefoot, e.g. any fracture or previous surgeries in the forefoot
  • Persons who have previously received intermetatarsal treatment (Morton's neuroma or IMB) in the same foot, e.g. injection within 6 months or operation at any time
  • Exclusion from MRI scan only:
  • Persons with contraindications to participate in MRI scan
  • Persons with severely impaired renal function (GFR <30 ml/min)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Control groupMagnetic resonance imagingPatients with other rheumatic diseases and absence of forefoot pain.
Patient groupUltrasoundPatients with rheumatoid arthritis and forefoot pain.
Patient groupClinical foot evaluationPatients with rheumatoid arthritis and forefoot pain.
Patient groupMagnetic resonance imagingPatients with rheumatoid arthritis and forefoot pain.
Patient groupCorticosteroid injectionPatients with rheumatoid arthritis and forefoot pain.
Control groupUltrasoundPatients with other rheumatic diseases and absence of forefoot pain.
Patient groupPicture of the feetPatients with rheumatoid arthritis and forefoot pain.
Control groupPicture of the feetPatients with other rheumatic diseases and absence of forefoot pain.
Primary Outcome Measures
NameTimeMethod
Change in Visual Analogue Score (VAS) scoreAt inclusion, 1 and 3 month(s) post treatment

Pain score related to the foot pain

Incidence of intermetatarsal bursitis on MRI8 weeks

High intensity on T2 weighted images, low signal on T1. Thin peripheral enhancement on T1 contrast enhanced pictures.

Incidence of intermetatarsal bursitis on US8 weeks

Hypoechoic mass between metatarsal heads. Activity on power/color doppler.

Incidence of other pathology on MRI8 weeks

Other than intermetatarsal bursitis

Incidence of other pathology on US8 weeks

Other than intermetatarsal bursitis

Secondary Outcome Measures
NameTimeMethod
Incidence of opening toes1 day

Presence of opening toes/V-sign/spreading toes.

Trial Locations

Locations (1)

Rigshospitalet Glostrup

🇩🇰

Glostrup, Denmark

© Copyright 2025. All Rights Reserved by MedPath